- 24 Tech Roqad st Ny 10023
- editech@mail.com
Statutory Communications
- Reconciliation of Share Capital Audit Report_31-03-2025
- Shareholding Pattern_31-03-2025
- Reconciliation Of Share Capital Audit Report_31-12-2024
- Shareholding Pattern_31-12-2024
- Update on Acquisition of NJ Bio
- Acquisition NJ Bio – Press Release & Investor Presentation
- Acquisition NJ Bio – Stock Exchange Intimation
- Shareholding Pattern_30-09-2024
- Reconciliation Of Share Capital Audit Report_30-09-2024
- Shareholding Pattern_30-06-2024
- Reconciliation Of Share Capital Audit Report_30-06-2024
- Annual Secretarial Compliance Report 2024
- Compliance Certificate Reg40(10)_31-03-2024
- Shareholding Pattern_31-03-2024
- Reconciliation Of Share Capital Audit Report_31-03-2024
- Shareholding Pattern_31-12-2023
- Reconciliation Of Share Capital Audit Report_31-12-2023
- Shareholding Pattern_30-09-2023
- Reconciliation of Share Capital Audit Report_30-09-2023
- Reconciliation of Share Capital Audit Report_30-06-2023
- Shareholding Pattern_30-06-2023
- Annual Secretarial Compliance Report 2023
- Shareholding Pattern_31-03-2023
- Reconciliation of Share Capital Audit Report_31-03-2023
- Shareholding Pattern_31-12-2022
- Reconciliation of Share Capital Audit Report_31-12-2022
- Shareholding Pattern_30-09-2022
- Reconciliation of Share Capital Audit Report_30-09-2022
- Shareholding Pattern_30-06-2022
- Reconciliation of Share Capital Audit Report_30-06-2022
- Annual Secretarial Compliance Report 2022
- Reconciliation of Share Capital Audit Report_31-03-2022
- Shareholding Pattern_31-03-2022
- ComplianceCertificateReg40(10)_31-03-2022
- Reconciliation of Share Capital Audit Report_31-12-2021
- Shareholding Pattern_31-12-2021
- Reconciliation of Share Capital Audit Report_30-09-2021
- Shareholding Pattern_30-09-2021
- Reconciliation of Share Capital Audit Report_30-06-2021
- Shareholding Pattern_30-06-2021
- Annual Secretarial Compliance Report 2021
- Reconciliation of Share Capital Audit Report_31-03-2021
- Compliance Certificate_Reg40(10)_ 31-03-2021
- Shareholding Pattern_31-03-2021
- Shareholding Pattern_31-12-2020
- Reconciliation of Share Capital Audit Report_31-12-2020
- Compliance Certificate_Reg40(10)_ 30-09-2020
- Reconciliation of Share Capital Audit Report_30-09-2020
- Shareholding Pattern_30-09-2020
- Reconciliation of Share Capital Audit Report_30-06-2020
- Shareholding Pattern_30-06-2020
- Shareholding Pattern_31-03-2020
- Reconciliation of Share Capital Audit Report_31-03-2020
- Compliance Certificate_Reg40(10)_31-03-2020
AGM
Notice of Board Meeting
Notices
Scheme of Arrangements
- Information Memorandum 04-March-2020
- Apportionment of Cost of Acquisition of Shares – SLSL & SPL
- Suven Pharmaceuticals Demerger Listing PA Clipping Financial Express 05.03.2020
- Suven Pharmaceuticals Demerger Listing PA Clipping Nava Telangana 05.03.2020
- Suven Pharmaceuticals Demerger Listing PA Clipping Jansatta 05.03.2020
Unpaid Dividend
Postal Ballot
Scheme of Amalgamation
- Allotment of shares pursuant to Scheme of Amalgamation
- Intimation of Effective Date of Merger and Record Date
- Intimation of DOP Approval – Merger of Cohance into and with Suven Pharma
- Order copy issued by Hon`ble NCLT – Merger of Cohance with and into Suven Pharma
- Summary of Proceedings, Voting Results and Scrutinizer’s Report of the NCLT convened Shareholders Meeting
- Newspaper Publication – Notice of General Meeting
- Notice of NCLT Convened Shareholders Meeting
- Summary working of proposed amalgamation
- Additional documents submitted to Stock Exchanges
- Copy of NCLT Order dated 22.10.2024
- Observation Letter – BSE
- Observation Letter – NSE
- Complaints Report – NSE
- Complaints Report – BSE
- Draft Scheme
- Valuation Report
- Fairness Opinion
- Audit Committee Report
- Independent Directors Committee Report
- Pre-Post Shareholding Pattern
- Accounting Treatment Certificate
- Audited Financials on unlisted company
- Declaration for No Past Defaults
- Compliance Report
Stock Exchange Communications
- Outcome of the Board Meeting held on June 26, 2025
- Schedule of the Roadshow on June 26, 2025
- Schedule of the Roadshow on June 25, 2025
- Sale of assets of CR Bio unit
- Schedule of the Roadshows on June 18 & 19, 2025
- Schedule of Roadshow on June 06, 2025
- FY2025 – Concall Transcript
- Annual Secretarial Compliance Report 2025
- Credit Rating May 28, 2025
- Schedule of Conferences on May 29, 2025
- General Update – USFDA Inspection
- Q4_Schedule of Conference Call for Investors on May 28, 2025
- Change in name and trading symbol
- Allotment of shares pursuant to Scheme of Amalgamation
- Press Release regarding change in name of the Company
- Change in Name of the Company
- Press Release – Effective date for Scheme of Amalgamation
- Intimation of Effective Date of Merger and Record Date
- Cautionary Email from NSE
- Cautionary Email from BSE
- Schedule of B&K, Macquarie Roadshow on March 31, April 1, 2 & 3, 2025
- USFDA Audit Related Press Release – Cohance
- Schedule of Conferences on March 11 & 12, 2025
- Schedule of B&K Roadshow on February 28, 2025
- Analyst Day on February 27, 2025
- Schedule of Conferences on February14 – 21, 2025
- Investor Presentation – January 2025
- Schedule of Conferences/Roadshows on January 13 – 16, 2025
- Update on Acquisition of NJ Bio
- Acquisition NJ Bio – Schedule of Conference Call for Investors_09122024
- Acquisition NJ Bio – Press Release & Investor Presentation
- Acquisition NJ Bio – Stock Exchange Intimation
- Schedule of Conferences/Roadshows on December 5, 2024
- Schedule of meet on December 4, 2024
- Credit Rating 29-Nov-2024
- Schedule of Conference/Roadshow on November 25, 2024
- Schedule of conferences/roadshows
- Schedule of Conference Call for Investors on June 19, 2024
- Outcome of Board Meeting 13/06/2024
- Outcome of Board Meeting 30/05/2024
- Schedule of Conference Call for Investors on May 30, 2024
- Schedule of Conference Call for Investors on November 12, 2024
- Schedule of Analyst Meet on September 30, 2024
- Outcome of Board Meeting 19/09/2024
- Schedule of Analyst Meet on September 18, 2024
- Credit Rating 05-Sept-2024
- Schedule of Analyst Meet on September 11, 2024
- Schedule of Analyst Meet on September 04, 2024
- Schedule of Analyst Meet on August 22, 2024
- Schedule of Conference Call for Investors on August 09, 2024
- Schedule of Analyst Meet on March 27, 2024
- Credit Rating 11-Mar-2024
- Press Release 29th Feb’24
- Schedule of Conference Call for Investors on March 05, 2024
- Investor Presentation 29th Feb’24
- Outcome of Board Meeting 29/02/2024
- Outcome of Board Meeting 29/02/2024
- Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015
- Outcome of Board Meeting 05/02/2024
- Disclosure under Regulation 31A(8)(d)
- Disclosure under Regulation 31A
- Outcome of Board Meeting 29/09/2023
- Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 29 09/2023
- Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 26/09/2023
- Schedule of Conference Call for Investors on August 10, 2023
- Schedule of Conference Call for Investors on May 26, 2023
- Disclosure under Regulation 30 of LODR
- Schedule of Conference Call for Investors on February 7, 2023
- Conference Call Transcript on December 26, 2022
- Conference Call Audio on December 26, 2022
- Schedule of Conference Call for Investors on December 26, 2022
- Disclosure under Regulation 30
- Schedule of Conference Call for Investors on November 9, 2022
- Casper Pharma Receives EIR from USFDA for its PAI (pre-approval inspection)
- Outcome of the Board Meeting 02/09/2022
- Schedule of Conference Call for Investors on August 08, 2022
- Casper Pharma completed USFDA pre-approval inspection
- Transcript of the earnings for the Analyst Meet on June 01, 2022
- Analyst Meet Audio recording on June 01, 2022
- Schedule of Analyst Meet on June 01, 2022
- Schedule of Conference Call for Investors on May 10, 2022
- SUVENPHARM Outcome of Board Meeting 05-04-2022